Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

Study Overview
=================
Brief Summary
-----------------
The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension. It consists of 3 phases: Screening, Treatment and Follow-up. During the Screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the Baseline visit, the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study, patients will be asked to repeat the right heart catheterization and exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.

Official Title
-----------------
Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: Bosentan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Screening Criteria: Males or females ≥ 12 years of age with a documented history of SCD Patients with symptomatic PAH associated with shortness of breath Patients with tricuspid regurgitation jet (TRJ) velocity of > 2.9 m/sec based on echo/Doppler conducted within 6 months prior to randomization and not during SCD crisis Signed written informed consent is obtained from the patient or patient's parent/legal representative prior to initiation of any study related procedure Inclusion Criteria: Patients with hemoglobin (Hb) SS or Hb S/β0 genotype and with Hb A ≤ 10% Six-minute walk test (6MWT) distance ≥ 150 m and ≤ 450 m PAH confirmed by right heart catheterization (RHC) performed at the study site within 3 months of the randomization visit and defined as: Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg measured by RHC or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg measured by left heart catheterization, if PCWP measurement is not reliable Pulmonary vascular resistance (PVR) at rest ≥ 160 dyn.sec/cm5 Women of childbearing potential must have a negative result on their serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination Exclusion Criteria: Left ventricular ejection fraction < 40% (echo/Doppler) Systolic blood pressure < 85 mmHg Uncontrolled hypertension with systolic blood pressure >160 mmHg and/or diastolic blood pressure > 100 mmHg Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) < 0.5 Total lung capacity (TLC) < 50% of normal predicted value Significant cardiac disease: ischemic, valvular, constrictive Hemoglobin concentration < 6.0 g/dL at the time of randomization Acute liver disease Evidence of cirrhosis or portal hypertension on a liver ultrasound or biopsy ALT ≥ 2 times upper limit of normal (ULN) and/or albumin < 2.8 g/dL Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent claudication, symptomatic hip osteonecrosis Vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 2 weeks of randomization or more than 12 VOC and/or ACS within the last 12 months Blood transfusion within 4 weeks prior to randomization Illness with a life expectancy shorter than 6 months HIV with opportunistic infection Psychotic, addictive, or other disorder limiting the ability to provide informed consent or to comply with study requirements Pregnant or lactating women Recently started (< 8 weeks prior to randomization) or planned, exercise-based cardio-pulmonary rehabilitation program Bone marrow transplantation Treatment or planned treatment with another investigational drug within 3 months prior to randomization Treatment for pulmonary hypertension with an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 3 months prior to randomization or with L-arginine within 1 week prior to randomization Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus), sirolimus, fluconazole, amiodarone, miconazole and glibenclamide (glyburide) within 1 week prior to randomization Known hypersensitivity to bosentan or any of its excipients

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br> | |
| Experimental: 2<br> | Drug: Bosentan<br>* Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline to End of Study in 6MWT distance. A mean difference from placebo of at least 35 m is considered clinically relevant. |  | 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to clinical worsening from Baseline to EOS. |  | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Arterial Hypertension, Pulmonary hypertension, Sickle Cell Disease, Sickle cell anemia, ASSET, ASSET-1